- About the Center
- Research Programs
- Addiction Genetics and Pharmacogenetics Division
- Addiction Treatment and Medication Development Division
- Brain-Behavioral Vulnerabilities Laboratory
- HIV/AIDS Prevention Research Division
- Clinical Trials Network
- Novel Interventions in Criminal Justice Populations Division
- Continuing Care and Assessment Division
- Integrated Care for Primary Care
- Clinical Trial Participation
- Treatment Options
- Affiliated Divisions
- Center Faculty
- Post Doctoral Fellowships
- Public Education and Policy Work
- Contact Us
- Support Our Work
Novel Interventions in Criminal Justice Populations Division
A large randomized trial of oral naltrexone in probationers with opiate dependence has recently been completed. The Division concluded a pilot multi-site trial of depot (injectable) naltrexone. Currently, the Division is the lead site for a large scale multi-site study. In this study, a total of 308 opiate-dependent patients who are on probation or parole were randomized to receive either monthly depot naltrexone injections or treatment-as-usual in an effort to study relapse in this population. The Division is also beginning a clinical trial of depot naltrexone in the management of repeat DUI offenders.
Cornish, J.W., Metzger, D., Woody, G.E., Wilson, D., McLellan, A.T., Vandergrift, B. and O’Brien, C.P.: Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment, 14(6):529-534, 1997.
O’Brien, C.P. and Cornish, J.W.: Naltexone for probationers and parolees. Journal of Substance Abuse Treatment, 31:107-11, 2006.
Back to Top